Rationale and design of phase II clinical trial of dual inhibition with ramucirumab and erlotinib in exon 19 deletion-positive treatment-naïve non-small cell lung cancer with high PD-L1 expression (SPIRAL-3D study)

Rationale and design of phase II clinical trial of dual inhibition with ramucirumab and erlotinib in exon 19 deletion-positive treatment-naïve non-small cell lung cancer with high PD-L1 expression (SPIRAL-3D study)

Background: Osimertinib is a standard treatment option for epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). However, osimertinib monotherapy yields poor clinical outcomes in some patients, necessitating the development of novel treatment strategies. In ad...

Full description

Bibliographic Details
Main Authors: Hayato Kawachi, Tadaaki Yamada, Akihiro Yoshimura, Kenji Morimoto, Masahiro Iwasaku, Shinsaku Tokuda, Young Hak Kim, Takayuki Shimose, Koichi Takayama
Format: Article
Language:English
Published: SAGE Publishing 2023-06-01
Series:Therapeutic Advances in Medical Oncology
Online Access:https://doi.org/10.1177/17588359231177022

Internet

https://doi.org/10.1177/17588359231177022

Similar Items